• cgoddard

  • Colin Goddard, Ph.D.
    Chairman & CEO

    Colin Goddard serves as Chairman & CEO of BlinkBio Inc. having joined the company as an angel investor and executive chairman in 2011. Dr. Goddard is actively involved as an investor, executive and board member in a number of early stage biotechnology companies, leveraging over 25 years of experience in the industry. From October 1998, until its $4 billion acquisition by Astellas Pharmaceuticals, Inc. in June of 2010, Dr. Goddard was CEO of OSI Pharmaceuticals, Inc. a company he joined as a scientist in 1989. In this role he raised over $1.5 billion and oversaw the development, approval and commercial launch of Tarceva®, a leading lung cancer medicine. He is Chairman of the Board of Mission Therapeutics and a member of the board of Endocyte (NASDAQ: ECYT), and has been active in many organizations that promote the advancement of cancer treatment and awareness, science education and the biotechnology industry. He received his PhD in Cancer Pharmacology in the UK in1985 and conducted his post-doctoral research at the National Cancer Institute in Bethesda, MD.

  • mpingle

  • Maneesh Pingle, Ph.D.

    Maneesh Pingle is a scientific cofounder of the company. As Research Assistant Professor at the Weill Medical College of Cornell University, he collaborated with BlinkBio making important contributions to the early proof-of-concept work for the Coferon platform. Maneesh joined BlinkBio in 2012 and oversees business development, collaborations and operations. He brings a multidisciplinary scientific background with training in pharmacy, medicinal and nucleic acid chemistry and molecular biology. He received his Ph.D. from Purdue University and his Bachelor’s degree in Pharmacy from the Bombay College of Pharmacy (India).

  • jwanner

  • Jutta Wanner, Ph.D.
    Vice-President, Research

    Jutta Wanner joined BlinkBio in August 2013 as Director of Chemistry. Jutta has over 10 years of experience and has led chemistry efforts in areas ranging from kinase to protein-protein interaction targets and from HTS to fragment approaches. She brings expertise across multiple therapeutic areas including oncology, inflammation and virology. At Hoffmann-La-Roche in Nutley, she served as the Head of the Medicinal Chemistry II Department, and, as a member of the Leadership team, she co-led Discovery Chemistry. Jutta received her PhD from the University of Kansas and her postdoctoral training at The Scripps Research Institute.